Global Bone Cancer Market Size, Share, Forecast Report, 2020-2027

As the name indicates, bone cancer develops in the skeletal system and degrades bone tissues. Bone cancer can be benign or malignant. Persistent bone pain, lump over bones, and weakness of bones are some of the common symptoms for the disease. If such symptoms remain unchecked, bone cancer can become life-threating. Thus, timely diagnosis and treatment of the disease is crucial. This provides the developmental backgrounds for market growth.

From the past few years, it has been observed that the prevalence of bone cancer has increased. Approximately 3,500 people were diagnosed with primary bone cancer in the US in 2018. Moreover, favorable reimbursement policies, increasing healthcare expenditure, rising R&D investments by the market key players, and growing awareness are estimated to drive the bone cancer market during the projected period. Therapeutic surgeries, including ablation therapy (against bone disease), are reimbursed under CPT code 20982. Such policies increase the number of patients who seek treatment for bone cancer.

However, the high cost of medicinal therapies and related side effects followed by poor healthcare infrastructure in developing countries is restricting the market growth.

Bone Cancer Market is estimated to grow at a healthy CAGR of 5.6% from 2018–2025.

Segmentation

The Global Bone Cancer Market has been segmented into type, diagnostic test & treatment, end user, and region.

The global market, based on type, has been divided into anterior bone cancer and posterior bone cancer. The anterior bone cancer segment is further segmented into diffuse bone cancer, nodular bone cancer, and necrotizing bone cancer.

The global market, by diagnostic test & treatment, has been divided into diagnostic test and treatment. The diagnostic test segment is further divided into ultrasonography, complete blood count, biopsy, and others. The treatment segment is bifurcated into medication and surgery. The medication segment is sub-segmented into corticosteroid, nonsteroidal anti-inflammatory drugs, and immunosuppressive drugs. The corticosteroid segment is sub-segmented into difluprednate, prednisolone, and others. The nonsteroidal anti-inflammatory drugs segment is further segmented into aspirin, ibuprofen, and others. The immunosuppressive drugs segment is sub-segmented into methotrexate, mycophenolate, and others.

The end-user segment has been segmented into hospitals & clinics, diagnostic centers, and academic & research organizations.

Key Players

Amgen, Amneal Pharmaceuticals LLC, Baxter International Inc., Boehringer Ingelheim, Fresenius Kabi USA, LLC, Jubilant Cadista Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Novartis Pharmaceuticals, Perrigo Company, Roxane Laboratories, Inc., Sandoz Inc., Shanghai Henlius Biotech, Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals, Zydus Pharmaceuticals (USA) Inc. are some of the key players operating in the global bone cancer market.

Global Bone Cancer Market, by Type

• Anterior Bone Cancer
  • Diffuse Bone Cancer
  • Nodular Bone Cancer
  • Necrotizing Bone Cancer
• Posterior Bone Cancer

Global Bone Cancer Market, by Diagnostic Test & Treatment

• Diagnostic Test
  • Ultrasonography
  • Complete Blood Count
  • Biopsy
  • Others
• Treatment
  • Medication
  • Corticosteroid
    • Difluprednate
    • Prednisolone
    • Others
  • Nonsteroidal Anti-Inflammatory Drugs
    • Aspirin
    • Ibuprofen
    • Others
  • Immunosuppressive Drugs
    • Methotrexate
    • Mycophenolate
    • Others
  • Surgery

Global Bone Cancer Market, by End User

• Hospitals & Clinics
• Diagnostic Centers
• Academic & Research Organizations